Search

Your search keyword '"Lorenzatti, A. J."' showing total 48 results

Search Constraints

Start Over You searched for: Author "Lorenzatti, A. J." Remove constraint Author: "Lorenzatti, A. J."
48 results on '"Lorenzatti, A. J."'

Search Results

1. Cardio-Obstetrics Practice in Latin America: A Regional Survey of General Cardiologists

2. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention

3. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

4. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

5. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

7. Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert’s position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS)

11. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

12. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

13. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

17. A randomized trial of rosuvastatin in the prevention of venous thromboembolism

18. Additional file 1 of Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

19. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

20. Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

22. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

23. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

24. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

25. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

27. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

28. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

32. This title is unavailable for guests, please login to see more information.

33. This title is unavailable for guests, please login to see more information.

34. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

35. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

36. Atherogenic dislipidemia in Latin America: prevalence, causes and treatment

37. Dislipidemia aterogénica en Latino América: prevalencia, causas y tratamiento

39. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial

40. Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation

41. Evolocumab and clinical outcomes in patients with cardiovascular disease

43. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)

44. A randomized trial of rosuvastatin in the prevention of venous thromboembolism

45. Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

46. Reduction in C-Reactive Protein and Low-Density Lipoprotein Cholesterol and Cardiovascular Event Rates After Initiation of Rosuvastatin: A Prospective Study of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin Trial

47. Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

48. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Catalog

Books, media, physical & digital resources